Project Grant R01HL171205
Award Date
9/1/24
Completion Date
5/31/28
Dollars Obligated
$750K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $751,747 to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on the transcriptional and post-transcriptional regulation of cardiomyocyte maturation. The research aims to define key factors and signaling pathways that control the structural, functional, and electrophysiological maturation of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,137,498 to advance research on cardiac maturation and its impact on heart disease and regeneration. The grant, awarded to The Trustees of the University of Pennsylvania, will fund a multi-year research project to: 1) investigate how naturally-occurring genetic variants in cardiomyocyte (CM) regulatory regions contribute to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research into the Hippo-YAP signaling pathway and its role in cardiac regenerative repair. The $693,261 award, effective January 10, 2025 through December 31, 2028, aims to develop gene therapy strategies that can enhance cardiac function and promote regenerative responses following myocardial infarction. The research will...
This Project Grant award for $802,762.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research at The University of Texas Southwestern Medical Center to define the transcription factors and gene regulatory networks involved in human cardiac development, characterize genetic variants regulating cardiac gene programs, and assess the impact of coding and non-coding variants on molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $119,250 to the University of Pittsburgh to investigate the role of METTL14-mediated mRNA methylation in orchestrating postnatal cardiac development and maturation. The research aims to elucidate how this epigenetic regulatory mechanism impacts cardiomyocyte proliferation, differentiation, and hypertrophy, with a focus on BMP2/10 and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will fund a $252,854 research project to develop computational tools that can link single-cell RNA sequencing (scRNAseq) data to experimentally-testable predictions of cardiomyocyte subtype function. The key objectives are to: 1) use scRNAseq to characterize cardiomyocyte subtypes derived from induced pluripotent stem cells, 2)...
This $106,201 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on post-transcriptional regulation of direct cardiac reprogramming. The project, led by Dr. Xie at the University of North Carolina at Chapel Hill, aims to 1) characterize the mechanisms by which the TBX5+siYBX1 cocktail generates induced cardiomyocyte-like cells from fibroblasts, and 2) elucidate how the...
This Project Grant award of $678,445.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to investigate the role of the novel protein C5ORF51 (C5X) in regulating cardiomyocyte function and homeostasis. The overarching hypothesis is that C5X, as a modulator of core cardiac transcription factors, plays a critical role in cardiomyogenesis and maintaining normal cardiac function. The research project aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to improve the robustness and reproducibility of manufacturing human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) through the development of feedback-controlled closed-loop processes. The $590,283 award to the University of Wisconsin-Madison will support research to: 1) identify key differentiation failure modes through single-cell...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...